Among the remaining clinical trials retrieved, two are undergoing phase III: a cholesterol-rich, protein-free nanoemulsion of paclitaxel, that resemble low-density lipoproteins and can be IV administered for the treatment of atherosclerosis, and lipid NP with patisiran (ALN-TTR02), a siRNA to treat hereditary transthyretin (TTR) induced amyloidosis, made with an optimized ionizable cationic lipid, DLin-MC3-DMA (Kulkarni et al., 2018). Here, TTR is linked to atherosclerosis.